About Veeva Systems Inc. Class A Common Stock (VEEV)
Veeva Systems Inc is a leading provider of cloud-based software solutions tailored specifically for the global life sciences industry. The company offers a range of products designed to streamline and enhance various aspects of the pharmaceutical and biotech sectors, including research and development, regulatory compliance, and commercial operations. By leveraging advanced technology and data analytics, Veeva enables life sciences organizations to improve their efficiency, accelerate drug development processes, and ensure adherence to regulatory standards, ultimately contributing to better patient outcomes and innovation in healthcare. Read More
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Veeva Systems (NYSE:VEEV) and the rest of the vertical software stocks fared in Q2.
Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 3.5% in the afternoon session after JP Morgan upgraded the stock to Overweight from Neutral and raised its price target.
Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) fell 3.8% in the morning session after its second-quarter earnings report failed to impress investors, even though the results beat expectations.
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.7% year on year to $789.1 million. Guidance for next quarter’s revenue was better than expected at $791.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $1.99 per share was 4.7% above analysts’ consensus estimates.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 16.7% year on year to $789.1 million. Guidance for next quarter’s revenue was better than expected at $791.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $1.99 per share was 4.7% above analysts’ consensus estimates.
Veeva Systems (VEEV) reported Q2 FY2026 earnings, beating revenue and EPS estimates. Despite strong growth in its life sciences cloud services, the stock declined in after-hours trading.
Wall Street traded cautiously on Wednesday, with major indices little changed at midday as investors awaited NVIDIA Corp.‘s (NASDAQ:NVDA) second-quarter earnings after the bell.
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) will be reporting results this Wednesday after market close. Here’s what you need to know.
IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way.
